Furthermore, we reported the decreased concentration of SPRR1A in tumours and SPRR2A in margin samples in the group of patients with concomitant diseases such as cardiovascular diseases, kidney diseases, gastrointestinal diseases, and endocrine diseases, compared to the group of patients without concomitant diseases. Here, SPRR2A is linked to endocrine system disorder.